You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Harvard Business School

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,566,252

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,566,252 protect, and when does it expire?

Patent 9,566,252 protects OSPHENA and is included in one NDA.

This patent has forty-one patent family members in twenty-eight countries.

Summary for Patent: 9,566,252
Title:Method for the alleviation of dyspareunia in women
Abstract: This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.
Inventor(s): Halonen; Kaija (Rusko, FI), Kangas; Lauri (Lieto, FI), DeGregorio; Michael W. (Granite Bay, CA)
Assignee: HORMOS MEDICAL LTD. (Turku, FI)
Application Number:12/837,292
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,566,252
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,566,252

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes   Start Trial   Start Trial TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.